Finch Therapeutics Group (NASDAQ:FNCH) Shares Up 3% – Should You Buy?

Finch Therapeutics Group, Inc. (NASDAQ:FNCH)’s stock price traded up 3% on Wednesday . The stock traded as high as $7.6712 and last traded at $7.62. 2,538 shares were traded during mid-day trading, a decline of 49% from the average session volume of 5,025 shares. The stock had previously closed at $7.40.

Finch Therapeutics Group Stock Performance

The company’s fifty day moving average is $11.37 and its two-hundred day moving average is $12.70. The company has a market cap of $12.24 million, a price-to-earnings ratio of -0.86 and a beta of 1.18.

Finch Therapeutics Group Company Profile

Finch Therapeutics Group is a clinical-stage biopharmaceutical company focused on developing microbiome-based therapies to treat diseases driven by gut microbial imbalance. Leveraging its proprietary Microbial Ecosystem Therapeutics (MET) platform, Finch engineers defined consortia of live microbes designed to restore healthy microbiome function. Its lead candidate, CP101, is in late-stage development for prevention of recurrent Clostridioides difficile infection (rCDI), and the company is advancing additional programs in inflammatory bowel disease, autism spectrum disorder and other immune-mediated conditions.

Founded in 2015 as an outgrowth of research at Massachusetts General Hospital and the Massachusetts Institute of Technology, Finch Therapeutics is headquartered in Cambridge, Massachusetts.